Targeted therapy combinations with venetoclax superior to chemoimmunotherapy in frontline CLL

Share :
Published: 13 Jun 2022
Views: 109
Prof Barbara Eichhorst - The University of Cologne, Cologne, Germany

Prof Barbara Eichhorst presents data from the randomised phase III GAIA/CLL13 trial during a press conference at the EHA 2022 meeting.

The study evaluated targeted therapy combinations with venetoclax vs chemoimmunotherapy in chronic lymphocytic leukaemia patients.

Watch our interview with Dr Eichhorst here

Read the news story here